Expansion of the Pharmaceutical Business through the Supply of Topical Antifungal Agents
First written in FY2017-Q1. 7 of 17 entries say "Advanced", first in FY2018. Latest entry: FY2026-H1.
No other company in this theme has enough history to compare yet.
- FY2026-H1AdvancedAnnual report
「In the pharmaceutical business, sales of the topical antifungal agent luliconazole for toenail fungus and other domestic indications increased as inventory in the distribution channel was reduced and shipments to distributors accelerated, among other factors.」
Luliconazole sales increased against a backdrop of declining distribution-channel inventories and faster shipments to distributors, representing concrete progress in the pharmaceutical business. - FY2025Sluggish sales due to excess inventory held by distributorsAnnual report
「In the pharmaceutical business, sales of the topical antifungal agent luliconazole for toenail fungus remained sluggish due to the impact of excess inventory held by distributors.」
Regarding the topical antifungal business, excess inventory held by distributors for toenail fungus treatments was cited as a factor behind sluggish sales, in addition to the previously stated decline in overseas demand and other factors. - FY2025-H1RestatedAnnual report
「In the pharmaceutical business, sales of the topical antifungal agent luliconazole for toenail fungus remained sluggish.」
Regarding the pharmaceutical business involving topical antifungal agents, the company reconfirmed sluggish sales of luliconazole for toenail fungus. - FY2024-Q3Sluggish sales due to the end of sales in ChinaAnnual report
「In the pharmaceutical business, sales were sluggish following the discontinuation of luliconazole sales in China.」
Regarding the pharmaceutical business involving topical antifungal agents, the explanation of sluggish luliconazole sales has become more specific, citing the discontinuation of sales in China rather than lower overseas demand. - FY2024-Q1Sluggish sales due to lower overseas demandAnnual report
「In the pharmaceutical business, sales of the topical antifungal agent luliconazole remained sluggish due to lower overseas demand, among other factors.」
Regarding the pharmaceutical business involving topical antifungal agents, the company stated that luliconazole sales remained sluggish against a backdrop of lower overseas demand. - FY2023RestatedAnnual report
「In the pharmaceutical business, sales of topical antifungal agents remained firm.」
The company reconfirmed that sales of topical antifungal agents remained firm. - FY2023-Q3AdvancedAnnual report
「In the pharmaceutical business, sales of topical antifungal agents remained firm.」
The description has changed from sluggish sales of topical antifungal agents in previous filings to firm sales in the current quarter. - FY2023-Q1RestatedAnnual report
「Meanwhile, in the pharmaceutical business, sales of the topical antifungal agent luliconazole remained sluggish for both athlete's foot and toenail fungus treatments.」
The company reconfirmed that luliconazole sales remained sluggish for both athlete's foot and toenail fungus treatments. - FY2022Sluggish SalesAnnual report
「Meanwhile, in the pharmaceutical business, sales of the topical antifungal agent luliconazole remained sluggish as the number of outpatients at medical institutions declined due to the spread of COVID-19, among other factors.」
Against the previous trend of pharmaceutical business expansion through topical antifungal agents, the company described sluggish luliconazole sales against a backdrop of declining outpatient numbers. - FY2021AdvancedAnnual report
「Meanwhile, in the pharmaceutical business, sales of the topical antifungal agents luliconazole and lanoconazole in the athlete's foot segment increased.」
Sales of luliconazole and lanoconazole in the athlete's foot segment increased. - FY2021-Q3RestatedAnnual report
「In the pharmaceutical business, sales of the topical antifungal agent luliconazole increased.」
The company reconfirmed the increase in luliconazole sales. - FY2021-Q1AdvancedAnnual report
「In the pharmaceutical business, sales of the topical antifungal agent luliconazole in the toenail fungus segment increased.」
Sales of luliconazole in the toenail fungus segment increased, and the company described progress in the pharmaceutical business through topical antifungal agents. - FY2020-Q3AdvancedAnnual report
「In the pharmaceutical business, sales of the topical antifungal agents lanoconazole and luliconazole increased.」
The company described progress in expanding the pharmaceutical business through topical antifungal agents, driven by higher sales of lanoconazole and luliconazole. - FY2020-Q3AdvancedAnnual report
「In the pharmaceutical business, sales of the topical antifungal agents lanoconazole and luliconazole increased.」
The company described concrete progress in expanding the pharmaceutical business, driven by higher sales of lanoconazole and luliconazole. - FY2018AdvancedAnnual report
「In the pharmaceutical business, sales of the topical antifungal agent luliconazole in the toenail fungus segment remained strong.」
The company described concrete progress in expanding the pharmaceutical business, with strong luliconazole sales in the toenail fungus segment. - FY2016RestatedAnnual report
「Sales increased as we began supplying luliconazole, a topical antifungal agent, as the active pharmaceutical ingredient for Lulocon, a topical treatment for toenail fungus launched in April this year by Sato Pharmaceutical Co., Ltd. and POLA Pharma Inc.」
The company reconfirmed the start of active pharmaceutical ingredient supply of luliconazole for Lulocon and the resulting growth in pharmaceutical sales. - FY2017-Q1First statedAnnual report
「Meanwhile, pharmaceutical sales increased as we began supplying luliconazole, a topical antifungal agent, as the active pharmaceutical ingredient for Lulocon, a topical treatment for toenail fungus launched in April this year by Sato Pharmaceutical Co., Ltd. and POLA Pharma Inc., among other factors.」
The company states that it began supplying the active pharmaceutical ingredient for a new drug in April, contributing to higher pharmaceutical sales.